1 citations
,
January 2013 This review explores the therapeutic applications of bimatoprost, including its role in glaucoma treatment, hair growth stimulation, and potential effects on fat deposition, but reports no new experimental findings.
43 citations
,
July 2013 in “Pharmacological reviews” This article reviews the pharmacology of bimatoprost and prostamide F2α, highlighting bimatoprost's therapeutic applications in glaucoma, hair growth, and potential fat reduction, without reporting new experimental results.
2 citations
,
September 2023 in “PubMed” The studies reviewed found favorable treatment outcomes for hypopigmented scars using PGF2α agonists with no adverse events reported. However, the authors highlight the need for larger randomized controlled trials to better understand their effectiveness and long-term safety.
7 citations
,
March 2017 in “Actas Dermo-Sifiliográficas” This review summarizes recent therapeutic advancements in treating various forms of alopecia, including new applications of oral minoxidil, dutasteride, finasteride, Janus kinase inhibitors, and novel hair transplant techniques, without presenting original research results.
1 citations
,
July 2018 in “Elsevier eBooks” This review explores the current treatments for different types of alopecia, emphasizing the need for well-designed clinical trials and highlighting that most therapies are used off-label, as only androgenetic alopecia has FDA-approved drugs.
Different drugs are used to manage breeding, prevent or end pregnancy, and treat reproductive issues in dogs and cats.
31 citations
,
October 2010 in “Progress in lipid research” This review discusses the role of LPA(3) in embryo implantation and its genetic connection with prostaglandin signaling, but reports no new clinical results.
January 2025 in “Dermatologic Therapy” In this review, researchers explored key mechanisms underlying androgenetic alopecia, revealing how hormonal, oxidative, inflammatory, and lipid dysregulation suppress hair growth pathways and suggesting new therapeutic targets such as DP2 antagonists and microbiome modulators.
February 2008 in “Medical & surgical dermatology” Some treatments like topical oxygen and stem cells show promise for wound healing and hair growth, but evidence for modern dressings over traditional ones is limited.
5 citations
,
October 1988 in “Clinics in Dermatology” This article reviews various types of alopecia, their diagnostic features, and patterns, but presents no new clinical findings; the authors discuss multiple mechanisms and classification challenges.
29 citations
,
September 2018 in “Journal of the American Heart Association” This study found that EP 2 signaling is crucial for macrophage recruitment and inflammatory regulation in the injured heart, impacting cardiac repair processes.
4 citations
,
May 2012 in “Journal of Investigative Dermatology” This symposium discussed the role of lipids, inflammation, and stem cells in cicatricial alopecia but reports no new research findings; it highlights lipid pathways as significant in these hair disorders.
July 2026 in “Pharmacological Reports” In this pilot study, topical latanoprost acid was observed to increase hair count and improve hair follicle structure in women with androgenetic alopecia, with no serious adverse events, suggesting potential for further investigation to confirm its efficacy and safety.
35 citations
,
May 2015 in “Thrombosis Research” This review synthesizes knowledge on Prostaglandin E2's role in platelet biology and suggests that targeting PGE2 pathways could lead to personalized antiplatelet therapy without affecting hemostasis, but it presents no new results.
205 citations
,
March 2012 in “Science Translational Medicine” PGD2 stops hair growth and is higher in bald men with AGA.
162 citations
,
August 2002 in “Survey of Ophthalmology” This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.
105 citations
,
August 2010 in “Pharmacology & therapeutics” This article explores the potential of formyl-peptide receptor 2 agonists as innovative anti-inflammatory drugs, highlighting their ability to mimic the body's natural inflammation response, but it presents no new clinical findings.
60 citations
,
May 2015 in “Archives of dermatological research” This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.
35 citations
,
December 1979 in “Naunyn-schmiedebergs Archives of Pharmacology” These drugs raise prostaglandin-like material in dog blood, possibly causing blood vessel widening.
18 citations
,
February 2018 in “International Journal of Molecular Sciences” This study found that prostaglandin D2 promotes androgen receptor and AKT signaling in human dermal papilla cells through the DP2 receptor, potentially contributing to androgenetic alopecia.
2 citations
,
February 2014 in “Animal Biotechnology” This study reported that the PTGER2 gene is strongly expressed in cashmere goat skin and its expression tends to decrease from the anagen to telogen stages of the hair follicle cycle.
11 citations
,
March 2008 in “Experimental Dermatology” This study identified a thiazolidine dione derivative as a potential inhibitor of 15-PGDH that may enhance prostaglandin activity in hair follicles, suggesting its use to support hair regrowth treatments.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” This study identified that blocking the PTGDR2 receptor in human hair follicles in vitro and in mice reversed the hair growth inhibition caused by PGD2, suggesting a potential approach for treating alopecia.
105 citations
,
December 2009 in “Archives of dermatology” This overview discusses primary cicatricial alopecias, focusing on lichen planopilaris, and highlights the challenges in treatment and the progressive nature of hair loss despite symptom management, without providing new clinical results.
20 citations
,
January 2017 in “Actas Dermo-Sifiliográficas” This review discusses recent therapeutic advances in treating various types of hair loss, including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and hair transplant technologies, but reports no new clinical results.
27 citations
,
April 2017 in “Journal of Investigative Dermatology” The researchers reported that noncoding double-stranded RNA promotes wound-induced hair neogenesis in mice by modulating prostaglandin and Wnt levels.
48 citations
,
April 2013 in “Expert Opinion on Investigational Drugs” This article reviews emerging treatments for androgenetic alopecia, including topical 5-alpha-reductase inhibitors and prostaglandin modulators, but reports no clinical results and calls for further efficacy evidence, especially for PRP.
85 citations
,
April 2007 in “Dermatologic Clinics” This article reviews drug-induced hair changes, highlighting that while many drugs are occasionally linked to hair loss, this connection has been conclusively established for only a few, and such hair loss is typically reversible.
47 citations
,
August 2016 in “Fitoterapia” This article reviews mechanisms by which herbal ingredients may stimulate or inhibit hair growth, and it reports no new clinical findings while suggesting potential for developing hair loss treatments.
42 citations
,
March 2006 in “Drug Discovery Today: Therapeutic Strategies” This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.